ConductScience.org, home

Comparison · NCT00548860-10b6c836

Ferric Carboxymaltose (FCM) vs Standard Medical Care (SMC): Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Ferric Carboxymaltose (FCM) vs Standard Medical Care (SMC): Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC. Trial comparisons, record NCT00548860-10b6c836. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00548860-10b6c836

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.006020.002760.0131wilson
Risk in group 20.02150.01430.0324wilson
Risk difference, group 1 minus group 2-0.0155-0.0268-0.00537newcombe hybrid score
Risk ratio, group 1 over group 20.280.1140.687log
Odds ratio, group 1 over group 20.2750.1110.682log
Number needed to treat, for one fewer participant with the outcome on Ferric Carboxymaltose (FCM) than on Standard Medical Care (SMC)64.537.3186from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Ferric Carboxymaltose (FCM)Intravenous (IV) iron6996OG000
Group 2Standard Medical Care (SMC)SMC for postpartum and heavy uterine bleeding subjects with anemia221,022OG001

Outcome

Type
PRIMARY
Title
Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.
Description
Evaluate the safety of the maximum administered dose, 15 mg/kg (up to a maximum 1,000 mg) of FCM compared to SMC. The primary safety endpoint was the incidence of Serious Adverse Events (SAE's).
Time frame
From Day 0 through 30 days after the last dose of study drug.
Population

Source ClinicalTrials.gov

Trial

Title
Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
NCT number
NCT00548860
Phases
PHASE3
Conditions
Anemia
Interventions
Ferric Carboxymaltose, Standard Medical Care (SMC)
Lead sponsor
American Regent, Inc.
Results first posted
2015-05-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00548860-10b6c836